Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06904677

Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

View on ClinicalTrials.gov

Summary

The goal of this observational study is to learn how well urinary proteins can predict treatment response in patients with locally advanced colorectal cancer (LACC) undergoing neoadjuvant therapy. The main question it aims to answer is: Can urinary protein markers help predict and evaluate how patients with LACC respond to neoadjuvant therapy? Participants diagnosed with LACC will provide urine samples before and after neoadjuvant therapy. These samples will be analyzed using 4D deep urinary proteomics and machine learning to identify proteins linked to treatment response. Some participants' tumor tissues will also be used to create organoid models for further testing.

Official title: Predicting and Evaluating the Efficacy of Neoadjuvant Therapy in Colorectal Cancer Based on 4D Deep Urinary Proteomics Technology

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

OBSERVATIONAL

Enrollment

400

Start Date

2025-05-01

Completion Date

2029-05-01

Last Updated

2025-11-28

Healthy Volunteers

No

Locations (1)

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Chaoyang District, China